Fluvoxamine for Outpatient Treatment of COVID-19: A Decentralized, Placebo-controlled, Randomized, Platform Clinical Trial

Matthew W. McCarthy, Susanna Naggie, David R. Boulware, Christopher J. Lindsell, Thomas G. Stewart, G. Michael Felker, Dushyantha Jayaweera, Mark Sulkowski, Nina Gentile, Carolyn Bramante, Upinder Singh, Rowena J. Dolor, Juan Ruiz-Unger, Sybil Wilson, Allison DeLong, April Remaly, Rhonda Wilder, Sean Collins, Sarah E. Dunsmore, Stacey J. Adam, Florence Thicklin, George Hanna, Adit A. Ginde, Mario Castro, Kathleen McTigue, Elizabeth Shenkman, Adrian F. Hernandez, the Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV)-6 Study Group
doi: https://doi.org/10.1101/2022.10.17.22281178

Data Availability

Prior to deposition of the data in a public repository which will occur when the platform trial has concluded, persons may request the data by submitting a proposal. If the data can be used for the proposed purpose and it is consistent with the informed consent, then the data will be released under a Data Use Agreement.

Back to top
Posted November 01, 2022.
Download PDF

Supplementary Material

Data/Code
Email
Fluvoxamine for Outpatient Treatment of COVID-19: A Decentralized, Placebo-controlled, Randomized, Platform Clinical Trial
Matthew W. McCarthy, Susanna Naggie, David R. Boulware, Christopher J. Lindsell, Thomas G. Stewart, G. Michael Felker, Dushyantha Jayaweera, Mark Sulkowski, Nina Gentile, Carolyn Bramante, Upinder Singh, Rowena J. Dolor, Juan Ruiz-Unger, Sybil Wilson, Allison DeLong, April Remaly, Rhonda Wilder, Sean Collins, Sarah E. Dunsmore, Stacey J. Adam, Florence Thicklin, George Hanna, Adit A. Ginde, Mario Castro, Kathleen McTigue, Elizabeth Shenkman, Adrian F. Hernandez, the Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV)-6 Study Group
medRxiv 2022.10.17.22281178; doi: https://doi.org/10.1101/2022.10.17.22281178
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools

Subject Area